Mark Dudley
About Mark Dudley
Chief Scientific Officer at Adaptimmune Therapeutics plc
Mark Dudley serves as the Chief Scientific Officer at Adaptimmune Therapeutics plc. In this role, he led the early development of advanced T cell therapies. His work involved overseeing the creation of innovative therapies aimed at harnessing the power of T cells to combat various types of cancer.
Technical R&D Leadership at Novartis
Mark Dudley was a pivotal member of the technical R&D leadership team at Novartis. During his tenure, he contributed to the strategic development of cutting-edge therapeutic solutions. His influence spanned across numerous initiatives, enhancing Novartis's position in the biopharmaceutical sector.
Nearly Two Decades at National Cancer Institute
Mark Dudley's career includes nearly two decades at the Surgery Branch of the National Cancer Institute. Here, he was instrumental in the advancement of novel T cell therapies. His tenure was marked by significant contributions to experimental treatments for cancer patients.
Contributions to Experimental T Cell Therapies
Mark Dudley's expertise encompasses a wide range of experimental T cell therapies. He has been involved in the development of TIL, TCR-T, and CAR-T products. His work has significantly influenced the landscape of adoptive cell therapies and garnered attention for its innovative approach to cancer treatment.
PhD in Biological Sciences from Stanford University
Mark Dudley received his PhD in Biological Sciences from Stanford University. His advanced education laid the groundwork for his impactful career in scientific research and development. Stanford's rigorous program equipped him with the knowledge and skills essential for his pioneering work in T cell therapies.